NEW ORLEANS, LOUISIANA--(CCNMatthews - March 26, 2007) - Resverlogix Corp. ("Resverlogix") (TSX:RVX), is pleased to announce that in preparation for the Investigational New Drug (IND) submission to the Food and Drug Administration (FDA) and Phase l Clinical trial the Clinical Advisory Board met in New Orleans in conjunction with the American College of Cardiology meeting. Resverlogix's lead drug candidate, RVX-208, is a first-in-class ApoA-I/HDL elevating small molecule which is undergoing IND-enabling studies and phase 1 human clinical study preparations. The excitement surrounding RVX-208 is linked to its high capacity to increase plasma ApoA-I/HDL levels by increased production of the ApoA-I protein, a biological process termed "ApoA-I enhancement".
ApoA-I, the key cardioprotective protein of HDL, is by the life sciences industry deemed to be the most important target for reducing cardiovascular disease risk and death. Increasing ApoA-I/HDL is projected to supersede and complement standard of care treatment for cardiovascular disease. Based on a unanimous recommendation from the Clinical Advisory Board, following a review of safety, hamster and primate ApoA-I/HDL effect data, Resverlogix is moving forward aggressively with its IND, Phase I and proof of concept clinical program for RVX-208.
"We have accomplished a great deal of scientific progress over the past several months with our lead compound especially in characterization of the safety and efficacy in multiple animal models," stated Dr. Jan Johansson, Senior Vice President Clinical Affairs, Resverlogix. "We are very proud to develop this novel ApoA-I/HDL enhancing compound and appreciate the guidance by the esteemed Clinical Advisory Board including Drs. Bo Angelin, Phil Barter, Jacques Genest, Dan Rader and PK Shah. The committee supports the notion that ApoA-I enhancement (plasma ApoA-I/HDL increase by increased ApoA-I production) has the potential to substantially remove atherosclerosis from the blood vessels".
Dr. Daniel Rader, Associate Professor of Medicine and Director of Preventive Cardiology, University of Pennsylvania School of Medicine stated, "Few, if any, would doubt that increasing plasma ApoA-I/HDL by enhanced production would have beneficial effects on cardiovascular disease."
Cardiovascular disease (CVD) remains the leading cause of death in industrialized countries and is the largest cost driver to health systems. The American Heart Association estimates the direct and indirect costs of CVD in the United States alone for 2006 are US $403.1 billion. ApoA-I is the key protein in high-density lipoprotein (HDL or the "good cholesterol") and several landmark clinical studies have demonstrated the protective role of ApoA-I against cardiovascular disease.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company in the development of novel therapies for important global medical markets with significant unmet medical needs. The Company's primary focus is to conduct leading research, development and commercialization of novel therapeutics that address the main underlying cause of cardiovascular disease (CVD). The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address the unmet medical needs of burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet human diseases. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information, please visit our web site at www.resverlogix.com.
This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.
FOR FURTHER INFORMATION PLEASE CONTACT:
VP, Corporate Communications
(403) 256-8495 (FAX)
SVP, Business & Market Development
(403) 256-8495 (FAX)